Pharmaceuticals, Biotechnology and Life Sciences
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing…
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Immunovant (Nasdaq: IMVT) today announced that it will report its financial results…
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced…
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical…
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving…
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address…
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with…
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…